EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study

Louise Marie Cremer iD, Ullrich Bethe iD, Peter Borchmann iD, Veronica Di Cristanziano iD, Lutz Gieselmann iD, Sarah Grimm iD, Martin Hellmich iD, Julia Jakobs iD, Julia A Nacov iD, Julia M Neuhann iD, Juergen Prattes iD, Christoph Scheid iD und 5 weitere

JMIR Research Protocols · 2025

DOI: 10.2196/60675 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift JMIR Research Protocols, 2025. Verfasst von Louise Marie Cremer und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicin…. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Immunocompromised Host, Immunogenicity, Vaccine. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the availability of vaccines, immunocompromised patients are still at high risk for severe COVID-19. Vaccination has been proven to be an effective measure in preventing severe SARS-CoV-2 infections; however, data on B- and T-cell responses are lacking. While vaccination schedules for the general population have been defined, achieving immunogenicity in patients who are immunocompromised remains a challenge.

Objective

The primary objective is to analyze anti-spike–immunoglobulin G (IgG) titers after repeated messenger ribonucleic acid vaccinations in patients who are immunocompromised. Further objectives are to analyze data on humoral immune responses and to evaluate data on cellular immune responses.

Methods

This multicenter, prospective, noninterventional study aims to determine the immunogenicity and reactogenicity of an implemented standard-of-care COVID-19 vaccination strategy in patients who are immunocompromised. A total of 100 patients will be recruited at three study sites. Patients are eligible for study inclusion when they are 18 years or older, vaccinated according to the recent version of the COVID-19 vaccination standard, and if the patient is immunocompromised according to stage 3 of the classification “Stages of Immunosuppression.” The study analyzes B- and T-cell responses generated within the standard-of-care COVID-19 vaccination strategy. Additional blood samples will be drawn at each scheduled outpatient visit. Study-related blood samples will be used to extract ethylenediaminetetraacetic acid plasma and peripheral blood mononuclear cells for evaluation of B- and T-cell responses to COVID-19 vaccinations. For this study, no additional visits or invasive procedures will be performed in addition to standard care.

Results

As of August 2024, the study has enrolled 32 patients. The recruitment phase is still ongoing.

Conclusions

Results will be used to optimize vaccination and booster schedules for patients who are immunocompromised and to increase rates of protection against severe SARS-CoV-2 infections. Further, results may identify risk and treatment factors, which lead to low immune responses in patients vaccinated against COVID-19, as well as the impact of repeated vaccination on B- and T-cell responses. Trial Registration ClinicalTrials.gov NCT05597761; https://clinicaltrials.gov/study/NCT05597761 International Registered Report Identifier (IRRID) DERR1-10.2196/60675

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesImmunocompromised HostImmunogenicity, VaccineSARS-CoV-2AdultFemaleHumansMaleAntibodies, ViralImmunoglobulin GMulticenter Studies as TopicProspective StudiesVaccinationObservational Studies as Topic

Stichwörter der Autor:innen

COVID-19SARS-CoV-2communicable diseaseimmunocompromisedimmunosuppressioninfectious diseasesobservational studyvaccinationvaccine

Substanzen

Antibodies, ViralCOVID-19 VaccinesImmunoglobulin G

Autor:innen und Institutionen

  • Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Ger…
  • Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, Univer…
  • German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
  • Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany.
  • Department of Internal Medicine, Division of Infectious Diseases, Excellence Center for Medical Mycology (ECMM), Medical University of Graz, Graz, Austria.

ORCID-Profile: Louise Marie Cremer, Ullrich Bethe, Peter Borchmann, Veronica Di Cristanziano, Lutz Gieselmann, Sarah Grimm, Martin Hellmich, Julia Jakobs, Julia A Nacov, Julia M Neuhann, Juergen Prattes, Christoph Scheid, Rosanne Sprute, Gertrud Steger, Jannik Stemler, Sibylle C Mellinghoff, Oliver A Cornely

Zitieren

APA

Cremer, L. M., Bethe, U., Borchmann, P., Di Cristanziano, V., Gieselmann, L., Grimm, S., Hellmich, M., Jakobs, J., Nacov, J. A., Neuhann, J. M., Prattes, J., Scheid, C., Sprute, R., Steger, G., Stemler, J., Mellinghoff, S. C., & Cornely, O. A. (2025). Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study. JMIR Research Protocols. https://doi.org/10.2196/60675

Vancouver

Cremer LM, Bethe U, Borchmann P, Di Cristanziano V, Gieselmann L, Grimm S, et al. Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study. JMIR Research Protocols. 2025. doi:10.2196/60675

BibTeX
@article{Cremer2025,
  author = {Cremer, Louise Marie and Bethe, Ullrich and Borchmann, Peter and Di Cristanziano, Veronica and Gieselmann, Lutz and Grimm, Sarah and Hellmich, Martin and Jakobs, Julia and Nacov, Julia A and Neuhann, Julia M and Prattes, Juergen and Scheid, Christoph and Sprute, Rosanne and Steger, Gertrud and Stemler, Jannik and Mellinghoff, Sibylle C and Cornely, Oliver A},
  title = {Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/60675}
}
Kostenlos starten →